Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials
Individual response varies considerably, and some patients may respond better to one medication than the other
What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use
At the same time, it suppresses the production of pheomelanin, a lighter pigment with lower chemical stability, which, when exposed to UV radiation, increases free radical formation and the risk of cellular mutations
No current UK marketing authorisation was identified for KPV, BPC-157 or TB-500 as medicines for wound healing, inflammation, tissue recovery, gut disorders or cosmetic treatment
